Who
Rodney S. Markin
Director
Company insider
Files Form 4 as: Director, Cardiff Oncology; Director, Precipio.
In numbers
- Trades disclosed
- 37
- Buys
- 4
- Sells
- 0
- Bought
- $130K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 23 May 2007
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 27 Jun 2024filed 1 Jul 2024 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,700 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,700 at $0.00 | filing |
| 9 Mar 2022filed 10 Mar 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,800 at $0.00 | filing |
| 10 Jun 2021filed 14 Jun 2021 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 26 Mar 2021filed 29 Mar 2021 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $30K2,900 at $10.32 | filing |
| 17 Jun 2020filed 19 Jun 2020 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,858 at $0.00 | filing |
| 14 May 2020filed 18 May 2020 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $30K20,979 at $1.43 | filing |
| 20 Jun 2019filed 24 Jun 2019 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,734 at $0.00 | filing |
| 20 Jun 2018filed 9 Nov 2018 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $35K41,200 at $0.85 | filing |
| 20 Jun 2018filed 21 Jun 2018 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $35K41,200 at $0.85 | filing |
| 23 Jan 2018filed 25 Jan 2018 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,322 at $0.00 | filing |
| 2 Jan 2018filed 4 Jan 2018 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Code M | —16,667 at $0.00 | filing |
| 2 Jan 2018filed 4 Jan 2018 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,667 at $0.00 | filing |
| 4 Oct 2017filed 5 Oct 2017 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,106 at $0.00 | filing |
| 2 Sep 2017filed 6 Sep 2017 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Code M | —5,943 at $0.00 | filing |
| 2 Sep 2017filed 6 Sep 2017 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,943 at $0.00 | filing |
| 2 Jan 2017filed 5 Jan 2017 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,667 at $0.00 | filing |
News
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic LeukemiaCRDF · manilatimes.net · 21 Oct 2026Analyzing Cardiff Oncology (NASDAQ:CRDF) and Xencor (NASDAQ:XNCR)CRDF · themarketsdaily.com · 21 Oct 2026
0 headlines in the last 90 days name Rodney S. Markin; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.